Literature DB >> 8938448

Definition of the minimal MEN1 candidate area based on a 5-Mb integrated map of proximal 11q13. The European Consortium on Men1, (GENEM 1; Groupe d'Etude des Néoplasies Endocriniennes Multiples de type 1).

A Courseaux1, J Grosgeorge, P Gaudray, A A Pannett, S A Forbes, C Williamson, D Bassett, R V Thakker, B T Teh, F Farnebo, J Shepherd, B Skogseid, C Larsson, S Giraud, C X Zhang, J Salandre, A Calender.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder with a high penetrance characterized by tumors of the parathyroid glands, the endocrine pancreas, and the anterior pituitary. The MEN1 gene, a putative tumor suppressor gene, has been mapped to a 3- to 8-cM region in chromosome 11q13 but it remains elusive as yet. We have combined the efforts and resources from four laboratories to form the European Consortium on MEN1 with the aims of establishing the genetic and the physical maps of 11q13 and of further narrowing the MEN1 region. A 5-Mb integrated map of the region was established by fluorescence in situ hybridization on both metaphase chromosomes and DNA fibers, by hybridization to DNA from somatic cell hybrids containing various parts of human chromosome 11, by long-range restriction mapping, and by characterization of YACs and cosmids. Polymorphic markers were positioned and ordered by physical mapping and genetic linkage in 86 MEN1 families with 452 affected individuals. Two critical recombinants identified in two affected cases placed the MEN1 gene in an approximately 2-Mb region around PYGM, flanked by D11S1883 and D11S449.

Entities:  

Mesh:

Year:  1996        PMID: 8938448

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  6 in total

1.  A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus.

Authors:  S C Guru; S K Agarwal; P Manickam; S E Olufemi; J S Crabtree; J M Weisemann; M B Kester; Y S Kim; Y Wang; M R Emmert-Buck; L A Liotta; A M Spiegel; M S Boguski; B A Roe; F S Collins; S J Marx; L Burns; S C Chandrasekharappa
Journal:  Genome Res       Date:  1997-07       Impact factor: 9.043

2.  Multiple intracranial recurrent tumors with hyperprolactinemia combined with a parasellar malignant fibrous histiocytoma long after transfrontal surgery and irradiation to a pituitary adenoma.

Authors:  M Fujikawa; K Okamura; K Sato; M Shiratsuchi; T Yao; T Mizokami; M Fujishima
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

3.  Mapping, cloning, cDNA sequence, and expression of the gene encoding the mouse micromolar calpain large subunit.

Authors:  C Poirier; S Poussard; D M Faust; T Imaizumi-Scherrer; M C Weiss; A Ducastaing; D Montarras; C Pinset; J L Guénet
Journal:  Mamm Genome       Date:  1998-05       Impact factor: 2.957

4.  The mouse homologs of RELA and MLK3 are located within a 120-kb fragment on chromosome 19.

Authors:  M Fernandes; C Poirier; N J Lassam; C Larsson; J Guénet; P Gaudray; G F Carle
Journal:  Mamm Genome       Date:  1997-07       Impact factor: 2.957

5.  Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders.

Authors:  S Giraud; C X Zhang; O Serova-Sinilnikova; V Wautot; J Salandre; N Buisson; C Waterlot; C Bauters; N Porchet; J P Aubert; P Emy; G Cadiot; B Delemer; O Chabre; P Niccoli; F Leprat; F Duron; B Emperauger; P Cougard; P Goudet; E Sarfati; J P Riou; S Guichard; M Rodier; A Meyrier; P Caron; M C Vantyghem; M Assayag; J L Peix; M Pugeat; V Rohmer; M Vallotton; G Lenoir; P Gaudray; C Proye; B Conte-Devolx; P Chanson; Y Y Shugart; D Goldgar; A Murat; A Calender
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 6.  Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.

Authors:  A K Walch; H F Zitzelsberger; M M Aubele; A E Mattis; M Bauchinger; S Candidus; H W Präuer; M Werner; H Höfler
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.